Integer price target lowered to $152 from $160 at Argus

Argus lowered the firm’s price target on Integer (ITGR) to $152 from $160 and keeps a Buy rating on the shares. The firm cites the company’s Q4 earnings miss last week but notes that despite the pullback following the earnings report, it expects positive momentum to continue, the analyst tells investors in a research note. While there is potential for some disruption to the broader medical device industry from FDA resources and the potential for increased product tariffs, Integer’s sales and margins should continue to benefit from strong customer demand, the firm adds.